STAT+: GLP-1s are given an FDA warning for rare eye condition risk
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. We’ve got lots of news that we’ll get straight into. The need-to-know this morning Beam Therapeutics said its CRISPR-based treatment for sickle cell disease…















,xPosition=.5,yPosition=.5;Resize=(1200,675)&impolicy=medium)





































































































